Literature DB >> 22441153

Ten challenges for TB biomarkers.

Tom H M Ottenhoff1, Jerrold J Ellner, Stefan H E Kaufmann.   

Abstract

The availability of tuberculosis (TB) biomarkers of protection (or: "surrogate endpoints of protection against active TB" (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22441153     DOI： 10.1016/S1472-9792(12)70007-0

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


  19 in total

Review 1.  Metabolomics: Applications and Promise in Mycobacterial Disease.

Authors:  Mehdi Mirsaeidi; Mohammad Mehdi Banoei; Brent W Winston; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2015-09

2.  Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults.

Authors:  Mardi C Boer; Corine Prins; Krista E van Meijgaarden; Jaap T van Dissel; Tom H M Ottenhoff; Simone A Joosten
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

Review 3.  The role of biomedical research in global tuberculosis control: gaps and challenges: A perspective from the US National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Authors:  Christine F Sizemore; Amanda C Schleif; Jessica B Bernstein; Carole A Heilman
Journal:  Emerg Microbes Infect       Date:  2012-07-25       Impact factor: 7.163

4.  Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis.

Authors:  Tom H M Ottenhoff; Ranjeeta Hari Dass; Ninghan Yang; Mingzi M Zhang; Hazel E E Wong; Edhyana Sahiratmadja; Chiea Chuen Khor; Bachti Alisjahbana; Reinout van Crevel; Sangkot Marzuki; Mark Seielstad; Esther van de Vosse; Martin L Hibberd
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

5.  Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis.

Authors:  Rosa Sloot; Maarten F Schim van der Loeff; Erik W van Zwet; Mariëlle C Haks; Sytze T Keizer; Maarten Scholing; Tom H M Ottenhoff; Martien W Borgdorff; Simone A Joosten
Journal:  EBioMedicine       Date:  2014-12-02       Impact factor: 8.143

6.  Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses.

Authors:  Siri L Feruglio; Marius Trøseid; Jan Kristian Damås; Dag Kvale; Anne Ma Dyrhol-Riise
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

7.  Nonclinical Development of BCG Replacement Vaccine Candidates.

Authors:  Kamalakannan Velmurugan; Leander Grode; Rosemary Chang; Megan Fitzpatrick; Dominick Laddy; David Hokey; Steven Derrick; Sheldon Morris; David McCown; Reginald Kidd; Martin Gengenbacher; Bernd Eisele; Stefan H E Kaufmann; John Fulkerson; Michael J Brennan
Journal:  Vaccines (Basel)       Date:  2013-04-16

8.  Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa.

Authors:  Jayne S Sutherland; Maeve K Lalor; Gillian F Black; Lyn R Ambrose; Andre G Loxton; Novel N Chegou; Desta Kassa; Adane Mihret; Rawleigh Howe; Harriet Mayanja-Kizza; Marie P Gomez; Simon Donkor; Kees Franken; Willem Hanekom; Michel R Klein; Shreemanta K Parida; W Henry Boom; Bonnie A Thiel; Amelia C Crampin; Martin Ota; Gerhard Walzl; Tom H M Ottenhoff; Hazel M Dockrell; Stefan H E Kaufmann
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

9.  A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis.

Authors:  Simone A Joosten; Helen A Fletcher; Tom H M Ottenhoff
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

10.  Identification of biomarkers for tuberculosis susceptibility via integrated analysis of gene expression and longitudinal clinical data.

Authors:  Qingyang Luo; Smriti Mehra; Nadia A Golden; Deepak Kaushal; Michelle R Lacey
Journal:  Front Genet       Date:  2014-07-24       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.